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Endoscopy’s Unique Ability to Visualize and Accurately
Assess the Severity of Gastrointestinal
Graft-versus-Host-Disease
Prakash Varadarajan,1 Lauren M. Dunford,1 Julie A. Thomas,1 Karen Brown,1
Pamela Paplham,1 Margaret Syta,1 Michael Schiff,1 Swamithan Padmanabhan,1
Minoo Battiwalla,1 Shannon Smiley,1 Theresa Hahn,1 Philip L. McCarthy, Jr.1Early recognition of gastrointestinal graft-versus-host disease (GI GVHD) after allogeneic hematopoietic
stem cell transplantation (alloHSCT) is vital to initiation of therapy. However, the most common location,
the small bowel (SB), is difficult to access with upper and lower endoscopy (UGE/LGE). Wireless capsule
endoscopy (WCE) is a noninvasive technology allowing complete SB evaluation. The capsule location can
also be tracked to identify motility derangements. From August 2006 to July 2007, 11 alloHSCT patients
with GI symptoms underwent WCE, and visual grading was performed. UGE and LGE with biopsies were
done when clinically indicated. All patients had evidence of probable acute GVHD (aGVHD) on WCE.
WCE revealed lesions of greater severity than those seen by UGE or LGE in most patients. WCE demon-
strated that 45% of patients had delayed gastric transit time. WCE is an excellent, noninvasive method for
assessing GI GVHD, with the ability to more accurately assess the severity of GVHD, evaluate clinical symp-
toms, and follow response to treatment.
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Gastrointestinal graft-versus-host disease (GI
GVHD) is a frequent complication of allogeneic
hematopoietic stem cell transplantation (alloHSCT),
presenting with diarrhea, nausea, vomiting, abdominal
pain, anorexia, or hematochezia. One prospective
study identified GI GVHD as the sole culprit of per-
sistent GI symptoms in 81% of patients 20 days
beyond alloHSCT [1]. However, other conditions
may mimic the clinical presentation of GI GVHD.
Chemotherapeutic toxicity can account for similar
symptoms in the first 2 weeks post-alloHSCT [1,2].
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GVHD affects the GI tract in the absence of skin in-
volvement. Furthermore, the small bowel (SB), an
area that is difficult to access with traditional endo-
scopic methods, is the most common location of GI
GVHD [3]. Wireless capsule endoscopy (WCE) is
a noninvasive technology allowing for complete SB
evaluation, and has been successfully used in the diag-
nosis of occult bleeding and inflammatory bowel dis-
ease [3,4]. More recently, WCE has been used to
assess GI GVHD [5-7]. We evaluated the efficacy of
WCE in the diagnosis and evaluation of treatment re-
sponse of GI GVHD in symptomatic patients after
alloHSCT.MATERIALS AND METHODS
Patients and Data Collection
From August 2006 to July 2007, 11 alloHSCT
patients of median age 50 years (18–67), with symp-
toms of diarrhea, nausea, vomiting, abdominal pain,
or hematochezia underwent WCE to assist in diagno-
sis, assess therapy response, or evaluate other GI
pathology. Informed consent for WCE was obtained
from all patients. Concomitant studies including stool643
644 Biol Blood Marrow Transplant 15:643-648, 2009P. Varadarajan et al.bacterial, fungal, and viral cultures, Clostridium difficile
toxin assay. Blood Epstein-Barr virus (EBV) and cyto-
megalovirus (CMV) antigen testingwere also obtained.
Upper GI and lower GI endoscopy (UGE, LGE) were
performed, and biopsies taken when clinically indi-
cated. Patients 1 to 9 had symptoms typical of acute
GI GVHD, and had histology diagnostic of acute
GVHD (aGVHD) on the mucosal biopsy specimens.
All studies for pathologic infectious agents in mucosal
biopsy specimens were negative. Patients 1 to 9 had
concomitant UGE/LGE studies and WCE, allowing
for comparison of their results. Patients 10 and 11
had WCE alone. This study was approved by the
institutional review board of Roswell Park Cancer
Institute (RPCI).
Wireless Capsule Endoscopy
Patients drank up to 1 liter of polythethylene gly-
col electrolyte solution and/or clear liquids, the day
prior to the procedure. Patients were connected to
the recording device after a 12-hour overnight fast.
Two hours after swallowing the capsule (GIVEN
Imaging, Yoqneam, Israel), they were allowed to drink
clear liquids. The capsule recorded images at 2 per
second for a period of 8 hours, producing greater
than 50,000 images, which were analyzed by a single
gastroenterologist (M.S.). Visual grading of GI
GVHD was determined on a 5-point scale by Brand
et al. [8]: grade 0, normal; grade 1, loss of vascular
marking and/or mild focal erythema; grade 2, moder-
ate edema and/or erythema; grade 3, edema, erythema,
erosions, and/or bleeding; and grade 4, ulceration,
exudates, and bleeding. The following motility param-
eters were documented:
1. Gastric retention is defined as capsule remaining in
the stomach for 8 hours.
2. Gastric transit time (GTT) is defined as the time in
minutes between the first gastric image and the first
duodenal image.GTTwas considered delayed if the
pyloruswasnot reached in120minutes.The average
GTT in healthy patients is 10–60 minutes [9,10].
3. Small bowel transit time (SBTT) is the time in min-
utes between the first duodenal image and the first
image of the cecum.RESULTS
WCE for GVHD Imaging
The 11 patients underwent WCE at a median day
77 (range: 18-593) after alloHSCT (Table 1). No
patient had side effects attributable to WCE, and the
capsule was passed in all patients. The longest time to
passage was 14 days. No patients had positive CMV
antigenemia, EBV serologies, or C. difficile toxin assays
at the time of WCE. See Figure 1 for representativeWCE images. SB lesions visualized by WCE were
more severe than those seen on UGE/LGE in 7 out
of 9 of the patients who also had contemporaneous
UGE/LGE studies. The WCE studies had better
correlation with clinical appearance and severity of
diarrhea in 4 of 11 patients (patients 1, 2, 5, and 9) com-
pared to UGE/LGE and biopsy (see Table 1). Several
of the WCE studies showed lesions in a discontinuous
patternwith relative sparing of other small bowel areas.
For example, in patient 1, initial WCE showed severe
involvement of the proximal jejunum and distal ileum
with relative sparing of intervening areas. Repeat
WCE revealed differential healing with marked
improvement in the proximal jejunal lesions, whereas
the distal ileum continued to have several areas of
erosions and ulceration. Nine of the 11 patients had
corresponding UGE/LGE. All 9 patients had evidence
of GI GVHD present on biopsy.
Gastric Retention, Gastric, and SBTT
Two patients had gastric capsular retention
(patients 2 and 6). Patient 2 had UGE changes of
mild GVHD, which was confirmed by a duodenal
biopsy. Patient 6 had endoscopic evidence of severe
GVHDwithUGE revealing severe edema, hyperemia,
narrowing of the pyloric lumen, and LGE, revealing an
aperistaltic colon. The median GTT of the remaining
9 patients was 81 minutes (range: 4-236). Four patients
(1, 4, 5, and 10) had delayed GTT, and 3 of these
patients had significant nausea at the time of the
WCE study. The cecum was not visualized in 2 of
these patients (patients 1 and 4). The capsule was
endoscopically placed in the duodenum in patient 2
after gastric capsular retention and in patient 9 because
of severe vomiting. SBTT in 9 patients was a median
253 minutes (range: 162-444).DISCUSSION
GI GVHD has been considered a hypermotility
disorder because of the increasing diarrhea that can
accompany disease progression. We observed gastric
hypomotility in association with GI GVHD. Our
observed prevalence of 18% gastric retention of the
WCE is similar to that reported for acutely ill patients,
including patients withGVHD (24%) [9]. The average
GTT in healthy patients is 10-60 minutes but the clin-
ical significance of delayedGTTonWCEhas not been
well studied [9,10], nor have WCE-measured GTT
been compared with scintigraphic studies, the standard
for GTT measurement and gastroparesis diagnosis
[11]. Our findings are consistent with prior reports of
gastric dysmotility after HSCT. Eagle et al. [12],
performed scintigraphic gastric emptying studies in
18 autologous and alloHSCT patients with gastropa-
retic symptoms and found delayed GTT in 78%.
Table 1. Patient Characteristics, WCE, Endoscopic, and Histologic Results, Treatments, Modifications Based on WCE Results and Outcomes
Pt Age/Sex Dx
WCE day
post- HSCT WCE Lesions and Extent
EGS Grade
WCE*
UGE/LGE
(day post HSCT)
Lesions and Extent
EGS Grade
UGE/LGE*
GVHD Rx prior
to WCE
Changes
post-WCE Outcome
1 31/M AML 161 Erosions, ulcer, bleeding
(prox/mid jejunum); sparing
of mid/distal jejunum;
ulcer (distal ileum)
4 UGE/Flex Sig (160) erythema,
edema (stomach);
edema (rectum)
1-2 MP Started on
FK506,
MMF, MC
Steroids tapered,
continued on FK506,
sirolimus, infliximab, BDP,
MMF, and ATG,
and diarrhea subsided
on day 186
Repeat WCE on Patient 1 195 Edema, erythema (prox jejunum);
sparing of mid/distal jejunum;
erosions, ulcers (distal ileum)
2-4 Not repeated None MP, sirolimus, FK506,
ATG, infliximab,
BDP, MMF
MP tapered,
MC stopped
Diarrhea subsided in a week,
MP tapered, and patient
discharged on day 213
2 29/F AML 214 Edema, erythema (duodenum);
patchy erosions,
ulcer (mid jejunum)
2-4 UGE (212) hyperemia,
edema (stomach,
prox duodenum)
2 MP, BDP, FK506, MMF,
infliximab
None GI GVHD flare subsided
and pt was discharged
on day 223 on BDP, MMF,
and FK506
3 55/F ALL 55 Edema, erosions,
ulcers (jejunum)
2-4 UGE/LGE (30) edema
(stomach, prox
duodenum); erosions,
ulcers (hepatic flexure)
2-4 MP, sirolimus, FK506,
MMF, infliximab,
daclizumab
None GI GVHD subsided and
pt was discharged on
day 60 on FK506,
MMF, BDP, MP,
and sirolimus
4 57/F AML 99 Edema, erosions, ulcers,
blood clots (jejunum);
edema, erosions (ileum)
3-4 LGE (68) erythema,
edema, erosions,
ulcers (ascending colon)
1-4 MP, sirolimus, FK506,
MMF, infliximab, ATG
Daclizumab
added
Pt died on day 127
of refractory GI GVHD
5 50/M AML 593 Erosions (stomach, distal
jejunum, prox ileum)
3 UGE/LGE (589) hyperemia,
edema (stomach);
edema (colon)
2 BDP, MP, FK506,
MMF, infliximab, ECP
No change Abdominal symptoms
resolved and pt
discharged on day 614
6 40/F AML 37 Erosions, ulcers, blood clots
(stomach); capsule retained
in stomach
4 UGE/LGE (37) edema, ulcer,
bleeding (stomach, duodenum);
patchy ulcers (colon)
4 MMF, FK506, MP No change Pt died on day 77
of refractory GI GvHD
7 45/M AML 170 Ulcers (duodenum, jejunum);
erosions, ulcers (distal ileum)
3-4 UGE, jejunoscopy/LGE
(204) edema, patchy
erosions (jejunum);
ulcer (ileum); edema (colon)
2-4 MMF, cyclosporine,
MP (low dose)
MP increased Cystitis and lower GI bleeding
resolved. Pt discharged on
day 179 with MP taper
8 58/M NHL 18 Ulcers, erosions (prox jejunum) 3-4 LGE (15) edema, erythema
(ileum); edema, erythema
(sigmoid colon)
3-4 MMF, FK506, MP No change GI GvHD subsided and
discharged on day 25
9 67/F AML 32 Multiple erosions,
ulcers (jejunum)
3-4 UGE(32) erythema, edema
(stomach);edema (rectum)
2 FK506, MMF, MP Started on
infliximab
Pt died on day 39
of refractory GVHD
10 63/F MDS 161 Erythema, edema (stomach) 2 Not done Not done BDP, FK506,
MMF, MP, ursodiol
MP tapered,
MC started
Symptoms resolved and pt
discharged on day 168
11 18/F MDS 27 Patchy erosions (mid jejunum,
prox/mid ileum)
2-3 Not done Not done none None Pt discharged on day 29
tolerating oral food
WCE indicates wireless capsule endoscopy; Dx, diagnosis; Rx, therapy; GI, gastrointestinal; GVHD, graft-versus-host-disease; Dx, diagnosis; AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; NHL, Non
Hodgkin Lymphoma; MDS, myelodysplastic syndrome; ATG, antithymocyte globulin; BDP, beclomethasone dipropionate; MP, methylprednisolone 2 mg/kg unless marked as low dose, which is 1 mg/kg; MMF, myco-
phenolate mofetil; FK506, tacrolimus; MC, metoclopramide; EGS, endoscopic grading scale; HSCT, hematopoietic stem cell transplant; LGE, lower GI endoscopy; Flex Sig, flexible sigmoidoscopy; UGE, upper GI
endoscopy; prox, proximal.
*GVHD lesions ranged in severity in different locations A range is given when lesions varied by site.
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Figure 1. WCE imaging in patients with GI GVHD. (A) multiple gastric erosions; (B) erosions with ulcer in antrum; (C) proximal ileal erosion; (D) distal
ileal ulcer with deep, large clot.
646 Biol Blood Marrow Transplant 15:643-648, 2009P. Varadarajan et al.Wuet al. [1] evaluated persistent nausea and anorexia in
alloHSCT patients and found endoscopic evidence of
delayed gastric emptying, manifested by retained
food and bilious material. Thus, WCEmay be a useful
tool for prospectively andnoninvasively evaluating gas-
tric function during the posttransplant period.
WCE visualization of the entire SB allowed for
changes in management. Patient 1 was on MP prior
to WCE but after the results of the WCE indicated
Endoscopic Grading Scale (EGS) of 4 (versus 1-2 on
UGE/LGE), treatment was intensified (Table 1).
Repeat WCE indicated a decrease in the severity of
GvHD with a range of 2-4, indicating response to
adjustment of therapy. In patient 9, WCE more accu-
rately correlated with clinical outcome. Patient 9 had
EGS of grade 2 GI GVHD on UGE, but a range of
3 to 4 on WCE and ultimately succumbed to severe
GI GVHD (Table 1).
WCE findings may not differentiate mild GVHD
from other inflammatory conditions such as viral, bac-
terial infections. Ten percent of healthy patients may
have erythema, erosions, and small ulcerations on
WCE studies [13]. Thus, stool cultures for pathogens
as well as histopathologic confirmation by UGE/LGEis important for diagnostic confirmation. Another lim-
itation of WCE is the inability to visualize the entire
SB when there is delayed capsule passage. In our study,
the cecum was not visualized in 2 patients (patients 1
and 4) because of prolongedGTTor SBTT, and distal
SB lesions may have been missed. Several trials have
shown that administration of pro-kinetic agents such
as metoclopramide or erythromycin just before intro-
duction of the capsule or placing the patient in right
lateral position enhances the chances of study comple-
tion [9]. In rare circumstances, the capsule must be
retrieved by endoscopy or surgical intervention. In
our patient series we did observe capsule retention
for several days limiting the potential use of magnetic
resonance imaging during this time period. However,
all patients passed the capsule without endoscopic or
surgical intervention.
There are other noninvasive methods to assess GI
GVHD. High-resolution transabdominal ultrasonog-
raphy (HRU) and color Doppler imaging (CDI) have
been investigated. Patients with confirmed aGVHD
had bowel wall thickening primarily in the ileocecal
region [14]. CDI indicated an increased arterial
perfusion of the bowel wall and superior mesenteric
Biol Blood Marrow Transplant 15:643-648, 2009 647Impact of WCE on GI GVHDartery in patients with typical, but nonspecific signs in-
flammation and mucosal erythema and edema on
endoscopy. CDI also indicated decreased arterial per-
fusion in patients whose endoscopy yielded no bleed-
ing after biopsy [14]. Although this assessment
method is noninvasive, it does not directly observe
the intestinal mucosa. Thickening of the bowel wall
is nonspecific, and can be a result of infection [14].
F-fluorodeoxyglucose positron emission tomography
(FDG-PET) has also been investigated [15]. An in-
creased intestinal accumulation of FDG was seen in
14 out of 17 patients with GI GVHD compared to
0/13 patients without GVHD. FDG-PET was used
to monitor response to treatment [15]. Disadvantages
of FDG-PET are similar to the HRU and CDI
methods. There is no visualization of the intestinal
mucosa. Milligan et al. [16] used the Schilling test,
a measure of vitamin B12 absorption, with intrinsic
factor to examine the ileal vitamin B12 absorption af-
ter alloHSCT. There was abnormal B12 absorption
following the HSCT conditioning regimen, and it
was not possible to determine if acute GI GVHD
was associated with further decrease in absorption
of B12. Interestingly, chronic GVHD (cGVHD) pa-
tients (not limited to GI GVHD) had decreased vita-
min B12 absorption even in the absence of GI
symptoms [16].
WCE is a useful tool to diagnose GI GVHD in
both the acute and chronic setting, especially for doc-
umenting SB involvement. It is well tolerated and less
invasive than UGE/LGE. We found WCE to more
accurately assess and visualize the severity of GI
GVHD and better evaluate clinical symptoms. WCE
allowed for visual assessment of the response to ther-
apy. This is consistent with previous reports that endo-
scopic and histologic evaluations of the upper GI tract
can underestimate the severity of disease involvement
[17,18]. In patients with widespread severe GI
GVHD, WCE findings help establish the diagnosis
and extent of disease.WCEfindings were able to local-
ize the area of involvement, which is important because
of the intermittent nature of GI GVHD where lesions
can be scattered throughout the small intestine.
Lesions visualized on WCE were similar to those
seen on UGE/LGE and included erythema, erosions,
ulcers, and blood clots [18]. Being able to visualize
the mucosa proves advantageous, especially when
using WCE as a method of diagnosis and response to
treatment. Another benefit of WCE is that the entire
small bowel can be visualized, unlike UGE/LGE.
Thus, the clinician often would have to rely solely on
clinical manifestations. WCE will not eliminate the
need for invasive procedures such as UGE/LGE, as
it is still necessary to obtain a biopsy for histopatho-
logic diagnosis, but, it can significantly reduce the
number of times a patient is subjected to endoscopic
procedures. UtilizingWCE can visualize the intestinalmucosa and observe what was once seen only be inva-
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